:

Homeland Security

DoD Awards Morphotek $2.3M to Develop Biowarfare Therapies

DDN

Wednesday, October 3rd, 2007

SHARE:

Morphotek, Inc., a subsidiary of Japanese pharmaceutical company Eisai Co., received $2.3 million in funding from the Department of Defense to support the development of biologic- based monoclonal antibody therapies against biowarfare agents. Under the nine-month contract Morphotek will continue developing the therapies to treat Botulinum neurotoxins. "The further development of these compounds will enable us to advance these leads into clinical studies for validation and registration," says Nicholas Nicolaides, president and CEO of Morphotek.

Budget

Hegseth Pushes For Reconciliation With At Least $350 Billion For Defense ‘Regardless’ Of Midterms Outcome

Defense Secretary Pete Hegseth said Wednesday the Trump administration plans to continue its push for at least $350 billion in defense funds via the reconciliation process “regardless of what happens […]

Congress

Bipartisan Push in Senate to Hasten Export of 155 mm, GMLRS, HIMARS for Ukraine

A small, bipartisan group of senators is backing the Fast Tracking European Investment in Ukraine’s Defense Act, S. 5175, to hasten the export of allied buys of U.S. munitions for […]

Congress

Rep. Himes Signals Increased Contractor Oversight, if Democrats Win House

Rep. Jim Himes (D-Conn.), the ranking member of the House Permanent Select Committee on Intelligence, plans to increase the committee’s contractor oversight if the Democrats win control of the House […]

Congress

CBO Estimates Loss of One-Half to Two-Thirds of U.S. Missile Interceptors Since June Last Year

A new Congressional Budget Office report estimates the cost of the Iran war through Aug. 1 as $38 billion and says that the U.S. has likely depleted between one-half and […]